Annovis, Inc.

34 Mount Pleasant Drive
Aston
Pennsylvania
19014
United States

Tel: 610-579-1200
Fax: 610-579-1201

Email: info@annovis.com

Show jobs for this employer

10 articles with Annovis, Inc.

  • Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
  • The Company's common stock will begin trading under the symbol "ANVS" at the opening of trading on November 18, 2021.

  • The Annual Biomarkers for Alzheimer’s Disease Summit is running from August 25-26. Here’s a look at some of the top stories from day one.
  • Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit.     Event     Q1 Investor Summit   Date   March 23-25th, 2021   Presentation         March 24th @ 11:30AM ET  

  • Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at Benzinga's inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 4:30 pm ET. Investors interested in viewing Annovis Bio's presentation may register with free access  here  for the two-day

  • Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020.  Dr. Maccecchini and Mr. McGroarty will host virtual one-on-one meetings with investors to disc

  • Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced it resumed treatment of patients in its Phase 2a clinical trial in early AD patients following the suspension of the trial in March 2020 due to COVID-19.

  • Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be held in a digital format October 13-15, 2020. The company presentation will be available on demand during the virtual event for a

  • Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced its CEO, Maria Maccecchini, Ph.D., will appear on the Executive Leaders Radio program, airing nationally on Radio America on July 26, 2020 at 11 a.m.

  • Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 2020 Annual Meeting of Stockholders  in a virtual meeting format on Wednesday, June 3, 2020 at 10:00 a.m. (Eastern Time) at www.viewproxy.com/AnnovisBio/2020/VM . Shareholders of record that attend the Annual Meeting will be able to vote and submit ques